Skip to main content

Table 2 Five priority workstreams

From: CRIMALDDI: a co-ordinated, rational, and integrated effort to set logical priorities in anti-malarial drug discovery initiatives

Workstream No. Short Name Workshop Question
1 Pf & Pv novel targets & classes How to identify and exploit novel targets at all stages of the lifecycle of P falciparum & P vivax.
2 Managing the wealth of new HTS data Given the large number of molecular structures that have given positive hits in the HTS screens and which are now being released, how to develop systems to:-
      Make the information available to the community in an accessible way;
      Filter the structures with robust methods to identify those structures which are druggable and more promising starts for lead optimization;
      Allow the community to know who is working on which structures so that duplication can be avoided and resources not unnecessarily wasted.
3 Artemisinin resistance How to identify the mechanism(s) of artemisinin resistance in order to be able to design strategies to overcome or avoid it through novel combinations or novel molecular designs that counter the mechanism(s).
4 Stage-specific screening methods How to develop a complete set of robust and replicable screening methods that can be used to screen novel compounds for efficacy against the various stages of the Plasmodium parasite lifecycle.
5 Using chemistry to understand biology How to use the results of the whole cell screening of compounds for anti-malarial activity as a way of gaining insights into the underlying targets of different drug classes and then use this information to identify novel targets.
  1. The five priority workstreams identified by the Consortium's analysis to-date and endorsed by the EAG.